卵巢癌是发达国家妇女中最致命的妇科恶性肿瘤。尽管近年来有很多创新，但5年生存率的提高还不够，此类疾病的治疗仍然是一个挑战。事实上，大多数患者经历了复发或耐药病情，证实了创新治疗的必要性。在研究的各种策略中，基因递送技术方面近期的进展使得基因治疗，包括自杀基因策略成为治疗卵巢癌的潜在替代方案。各种自杀基因候选者能够通过酶编码、毒素或前凋亡基因将癌细胞凋亡直接促进或在临床管理期间通过前药静脉注射间接减轻器官不适。本文的目的是提供基于治疗策略的不同自杀基因概述，用于将这些转基因具体递送到恶性细胞的载体以及将这些基因与各种治疗方案结合使用。 ©2023版权所有。作者在Springer Nature America, Inc.独家许可下发布该文章。

Ovarian cancer represents the most lethal gynecological malignancy among women in developed countries. Despite the recent innovations, the improvements in the 5-year survival rate have been insufficient and the management of this disease still remains a challenge. The fact that the majority of patients experience recurrent or resistant disease have substantiated the necessity of an innovative treatment. Among various strategies investigated, the recent strides made in gene delivery techniques have made gene therapy, including suicide gene strategies, a potential alternative for treating ovarian cancer. Various suicide gene candidates, which are capable of promoting cancer cell apoptosis directly after its entry or indirectly by prodrug administration, can be separated into three systems using enzyme-coding, toxin or pro-apoptotic genes. With this review, we aim to provide an overview of different suicide genes depending on therapeutic strategies, the vectors used to deliver these transgenes specifically to malignant cells, and the combined treatments of these genes with various therapeutic regimens.© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.